Impact of preprocedural high-sensitive C-reactive protein levels on long-term clinical outcomes of patients with stable coronary artery disease and chronic kidney disease who were treated with drug-eluting stents  by Ogita, Manabu et al.
Journal of Cardiology 66 (2015) 15–21Original article
Impact of preprocedural high-sensitive C-reactive protein levels on
long-term clinical outcomes of patients with stable coronary artery
disease and chronic kidney disease who were treated with
drug-eluting stents
Manabu Ogita (MD, PhD), Katsumi Miyauchi (MD, FJCC)*, Takatoshi Kasai (MD, PhD),
Shinichiro Doi (MD), Hideki Wada (MD), Ryo Naito (MD), Hirokazu Konishi (MD),
Shuta Tsuboi (MD, PhD), Tomotaka Dohi (MD, PhD), Hiroshi Tamura (MD),
Shinya Okazaki (MD), Hiroyuki Daida (MD, FJCC)
Juntendo University, Department of Cardiovascular Medicine, Japan
A R T I C L E I N F O
Article history:
Received 12 September 2014
Received in revised form 3 October 2014
Accepted 14 October 2014






A B S T R A C T
Background: To evaluate the prognostic impact of preprocedural high-sensitivity C-reactive protein
(hsCRP) levels on the long-term clinical outcomes after ﬁrst-generation drug-eluting stent (DES)
implantation in chronic kidney disease (CKD) patients with stable coronary artery disease (CAD).
Methods and results: We found signiﬁcant interaction between CKD and hsCRP levels (p = 0.0138) in
1176 consecutive patients with stable CAD who were treated with ﬁrst-generation DES implantation
between 2004 and 2009 at our institution. Therefore, we separately analyzed data from patients with
and without CKD who were assigned to tertiles based on preprocedural hsCRP levels. We evaluated the
incidence of major adverse cardiovascular events (MACE) comprising all-cause death, nonfatal
myocardial infarction, and target vessel revascularization after percutaneous coronary intervention
during a median follow-up period of 1266 days. The rate of MACE signiﬁcantly differed among the
tertiles (log-rank p = 0.0074) in the group with CKD. Multivariate Cox regression analysis signiﬁcantly
associated a higher hsCRP tertile with MACE in the CKD group (hazard ratio 2.39, 95% conﬁdence interval
1.27–4.75, p = 0.0062).
Conclusion: Elevated preprocedural serum hsCRP levels might be associated with the long-term clinical
outcomes of patients with stable CAD and CKD who were implanted with ﬁrst-generation DES.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Atherosclerosis is fundamentally an inﬂammatory disease and
C-reactive protein (CRP) is an inﬂammatory biomarker that is an
independent predictor of adverse cardiovascular events in patients
with coronary artery disease (CAD) [1–4]. In addition, CRP is an
independent predictor of short-term adverse outcomes after
percutaneous coronary intervention (PCI) using bare metal
stents (BMS) [5]. The introduction of drug-eluting stents (DES)
considerably reduced restenosis rates [6,7], but restenosis remains* Corresponding author at: Department of Cardiovascular Medicine, Juntendo
University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Tel.: +81 3 3813 3111;
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0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardioloa major problem in some populations of patients such as those
with diabetes or renal impairment [8]. The predictive value of CRP
for long-term outcomes in these populations has not been fully
evaluated and remains controversial [9,10].
Chronic kidney disease (CKD) is an established risk factor for
the development of cardiovascular disease [11,12] and a potent
predictor of adverse clinical outcomes despite PCI with balloon
angioplasty or BMS [13,14]. Furthermore, restenosis and adverse
clinical outcomes remain major issues for patients with CKD
including those implanted with DES [8]. CKD is a result of a
combination of atherosclerosis that is accelerated through the
promotion of oxidative stress, endothelial dysfunction, and
vascular inﬂammation [15,16]. Thus, CKD per se might play major
roles in the development and progression of atherosclerosis and
related adverse clinical events, and in the development of
restenosis after PCI with DES. From this perspective, the presencegy.
M. Ogita et al. / Journal of Cardiology 66 (2015) 15–2116or absence of CKD might affect the ability of CRP to predict clinical
outcomes after PCI with DES.
The present study evaluates whether interactions between CKD
and CRP levels affect long-term clinical outcomes in patients with
stable CAD who were implanted with ﬁrst-generation DES.
Methods
Study population and data collection
This is a single-center, observational study of data from patients
who underwent scheduled PCI between August 2004 when DES
were adopted at Juntendo University Hospital and December
2009. Only the data from patients with stable CAD were assessed.
Patients with acute coronary syndrome (ACS) including unstable
angina pectoris (UAP) and acute myocardial infarction (AMI)
were excluded. In addition, patients with known malignancies,
active inﬂammatory diseases, and those with CKD stage
5 or receiving dialysis therapy were also excluded [17]. WeTable 1




T1 (n = 393)
<0.049 mg/dL
Age 66.5  9.4 66.0  9.1 
Male, n (%) 968 (84.0) 330 (84.0) 
Hypertension, n (%) 892 (75.9) 285 (72.5) 
Dyslipidemia, n (%) 928 (78.9) 309 (78.6) 
Diabetes, n (%) 588 (50.0) 191 (48.6) 
Current smoking, n (%) 258 (21.9) 72 (18.3) 
Family history, n (%) 365 (31.0) 127 (32.3) 
Multivessel Disease, n (%) 825 (70.3) 268 (68.2) 
Prior MI, n (%) 319 (28.7) 109 (29.4) 
Prior CABG, n (%) 119 (10.7) 31 (8.4) 
Prior PCI, n (%) 431 (38.8) 152 (41.0) 
LVEF 61.9  11.0 62.5  9.8 
BMI, kg/m2 24.5  3.2 24.0  2.9 
Waist circumference, cm 88.0  8.5 86.2  8.1 
SBP, mmHg 130.6  19.9 129.4  20.6 
DBP, mmHg 70.0  12.0 70.1  11.7 
LDL-C, mg/dL 107.3  30.3 104.5  29.2 
HDL-C, mg/dL 44.0  11.6 46.2  11.8 
TG, mg/dL 140.4  70.7 129.4  63.3 
FBG, mg/dL 109.7  32.9 105.9  32.0 
HbA1c, % 6.06  1.18 6.02  1.19 
eGFR, mL/min/1.73 m2 69.1  16.7 69.9  15.9 
CKD staging 
Stage 1, n (%) 119 (10.1) 43 (10.9) 
Stage 2, n (%) 696 (59.2) 242 (61.6) 
Stage 3, n (%) 355 (30.2) 107 (27.2) 
Stage 4, n (%) 6 (0.5) 1 (0.25) 
Medication
Aspirin, n (%) 1163 (99.2) 389 (99.5) 
Thienopyridines, n (%) 1150 (98.1) 384 (98.2) 
Ca-blockers, n (%) 506 (43.2) 165 (42.2) 
ACE inhibitors, n (%) 154 (13.1) 50 (12.8) 
ARBs, n (%) 476 (40.6) 161 (41.2) 
b-Blockers, n (%) 655 (55.9) 211 (54.0) 
Statins, n (%) 836 (71.4) 291 (74.4) 
Culprit of vessel 
LAD, n (%) 508 (43.2) 181 (46.1) 
LCX, n (%) 282 (24.0) 92 (23.4) 
RCA, n (%) 357 (30.4) 110 (28.0) 
LMT, n (%) 29 (2.4) 8 (2.0) 
Type of stents 
SES, n (%) 918 (78.1) 319 (81.2) 
PES, n (%) 258 (21.9) 74 (18.8) 
ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor 
chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁ
density lipoprotein cholesterol; LAD, left anterior descending coronary artery; LCX, lef
main trunk; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percu
artery; SBP, systolic blood pressure; SES, sirolimus-eluting stents; TG, triglyceride.deﬁned CKD as an estimated glomerular ﬁltration rate (eGFR)
of <60 mL/min/1.73 m2, and calculated the eGFR based on the
modiﬁcation of diet in renal disease equation modiﬁed with a
Japanese coefﬁcient using baseline serum creatinine [18].
Demographic data as well as information about coronary risk
factors and medications were extracted from our institutional
database. Blood samples were collected in the early morning
after an overnight fast and blood pressure (BP) was measured at
the time of admission. Patients with BP > 140/90 mmHg or under
anti-hypertensive medication were regarded as being hyperten-
sive. Dyslipidemia was deﬁned as low-density lipoprotein
cholesterol (LDL-C)  140 mg/dL, high-density lipoprotein choles-
terol (HDL-C)  40 mg/dL, triglyceride (TG)  150 mg/dL and being
treated with statins and/or lipid-lowering agents [19]. Diabetes
mellitus was deﬁned as either hemoglobin A1c (HbA1c)  6.5% or
under medication with insulin or oral hypoglycemic drugs. The
estimated HbA1c (%) was calculated as the National Glycohemo-
globin Standardization Program (NGSP) equivalent value (%) using




T3 (n = 392)
>0.164 mg/dL
p-Value
66.5  8.9 66.9  10.2 0.41
337 (86.2) 321 (81.9) 0.26
308 (78.8) 299 (76.3) 0.12
312 (79.8) 307 (78.3) 0.87
201 (51.4) 196 (50.0) 0.73
71 (18.1) 115 (29.4) <0.0001
115 (29.4) 123 (31.4) 0.67
267 (68.3) 290 (74.4) 0.10
102 (27.6) 108 (29.3) 0.83
47 (12.7) 41 (11.1) 0.15
144 (38.9) 135 (36.6) 0.47
62.4  10.9 60.6  12.1 0.12
24.6  2.9 24.9  3.6 0.0015
88.7  8.2 89.2  8.8 <0.0001
131.6  18.3 130.8  20.3 0.10
70.3  11.8 69.7  12.5 0.85
106.5  30.4 111.0  30.9 0.03
44.1  11.0 41.8  11.6 <0.0001
146.9  72.3 145.1  75.0 0.0001
112.6  36.1 110.5  34.5 0.0014
6.10  1.22 6.11  1.15 0.17
69.1  16.9 68.0  17.1 0.19
0.45
39 (10.0) 37 (9.4)
226 (57.8) 228 (58.2)
125 (31.9) 123 (31.4)
1 (0.3) 4 (1.0)
386 (99.0) 388 (99.2) 0.71
381 (98.7) 385 (98.5) 0.72
183 (46.9) 158 (40.4) 0.17
47 (12.1) 57 (14.6) 0.56
157 (40.3) 158 (40.4) 0.96
222 (56.9) 222 (56.8) 0.64
273 (70.2) 272 (69.6) 0.26
0.39
167 (42.7) 155 (39.5)
90 (23.0) 96 (24.5)
115 (29.4) 127 (29.1)
14 (3.6) 7 (1.8)
0.06
308 (78.8) 291 (74.2)
83 (21.2) 101 (25.8)
blockers; BMI, body mass index; CABG, coronary artery bypass graft surgery; CKD,
ltration rate; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HDL-C, high-
t circumﬂex coronary artery LDL-C, low-density lipoprotein cholesterol; LMT, left
taneous coronary intervention; PES, paclitaxel-eluting stents; RCA, right coronary
Fig. 1. Kaplan–Meier curves for major adverse cardiovascular events (MACE) in all
patients.
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levels.
Written informed consent was obtained from all patients before
undergoing coronary intervention. This study proceeded under the
approval from our institutional review board in accordance with
the Declaration of Helsinki.
Primary endpoint
The primary outcome was major adverse cardiac events (MACE)
deﬁned as a composite of all-cause death, ACS, and target vessel
revascularization (TVR). Clinical follow-up comprised analyses of
ofﬁce visit charts and responses to questionnaires sent to patients
or their families and telephone contact. MACE that occurred during
the initial hospitalization were excluded. Mortality data were
collected from the medical records of patients who died or who
were treated at our institution and details and causes of death were
obtained from other hospitals where patients had been admitted.
We deﬁned ACS as unstable angina (UAP), non-ST segment
elevation myocardial infarction (NSTEMI), or STEMI. UAP was
diagnosed as having angina at rest or in an accelerating pattern
with negative cardiac biomarkers, with or without electrocardio-
gram (ECG) changes indicative of myocardial ischemia. We deﬁned
myocardial infarction as troponin T positivity. TVR was considered
to be ischemia-driven if associated with a target vessel diameter
stenosis of 75% with ischemic symptoms, or a target vessel
diameter stenosis of 90% with or without documented ischemia.
Statistical analysis
Quantitative data are expressed as means  SD and categorical
variables are presented as frequencies. Patients were assigned to
tertiles based upon preprocedural hsCRP values. Continuous variables
across tertiles were compared using a one-way ANOVA or the
Kruskal–Wallis test. Categorical variables were compared using chi-
square statistics. Unadjusted cumulative event rates were estimated
using Kaplan–Meier curve and compared across tertiles. The effects of
hsCRP levels on MACE after PCI were determined using multivariable
Cox proportional hazard regression analysis. Age, gender, body mass
index (BMI), waist circumference, hypertension, diabetes, current
smoking, family history of CAD, CKD, prior myocardial infarction, left
ventricular ejection fraction (LVEF), triple vessel disease, type C
lesion, stent size, stent length, type of DES, and medication with
statins and angiotensin-converting enzyme inhibitors (ACE-I)/angio-
tensin receptor blockers (ARB) were selected as covariates from
among the baseline variables. To assess whether potential relation-
ships between hsCRP levels and MACE were affected by any other
covariates, we conducted Cox proportional hazard regression with
an interaction term between hsCRP levels and other covariates.
Thereafter, covariates with p < 0.05 in univariable analysis were
selected for multivariable analysis. Levels of hsCRP were included in
multivariate model, and hazard ratios (HRs) and conﬁdence intervals
(CIs) were calculated. We determined whether the results differed
from the cut-off points using secondary analyses in which hsCRP
levels were treated as a natural logarithm-transformed continuous
variable. Values with p < 0.05 were considered to indicate statisti-
cally signiﬁcant difference. All data were analyzed using JMP version
9.0 for Windows (SAS Institute, Cary, NC, USA).
Results
During the study period, 1218 patients underwent scheduled
PCI with ﬁrst-generation DES. Among them, we ﬁnally analyzed
data from 1176 eligible patients with stable CAD who were
treated with the ﬁrst-generation DES. Table 1 shows the baseline
characteristics of subjects according to the hsCRP tertiles.The median follow-up period was 1266 days (interquartile range,
675–1751 days) and prognostic data were fully documented
during the entire follow-up period. There were 197 (16.8%)
MACEs including 23 (2.0%) deaths, 64 (5.4%) ACS, and 110 (9.4%)
TVR. Fig. 1 shows the cumulative event-free survival curves for
MACE according to hsCRP tertiles. The curves of each tertile
signiﬁcantly differed (log-rank test, p = 0.002). Risk analyses using
Cox proportional-hazard models revealed a signiﬁcant interaction
between hsCRP levels and the presence or absence of CKD
(p = 0.0138). Therefore, we separately analyzed the presence
(n = 361) or absence (n = 815) of CKD.
Tables 2 and 3 show baseline clinical characteristics across
hsCRP tertiles of patients with and without CKD. Current smoking,
metabolic factors including BMI, waist circumference, HDL-C, and
triglycerides signiﬁcantly differed across tertiles in the group
without CKD, whereas only age signiﬁcantly differed across tertiles
in the group with CKD. A comparison of angiographic and
procedural characteristics compared across tertiles in each group
found no signiﬁcant differences across hsCRP tertiles in the group
with and without CKD.
Figs. 2 and 3 show Kaplan–Meier survival curves for MACE
stratiﬁed according to tertiles of preprocedural hsCRP levels in
patients with and without CKD, respectively. Rates of MACE among
tertiles (p = 0.17) did not signiﬁcantly differ in the group without
CKD, whereas the cumulative incidence of events signiﬁcantly
increased with increasing hsCRP levels in the group with CKD
(p = 0.0074). Table 4 summarizes the ﬁndings of univariate and
multivariate Cox hazard regression analyses. Variables with
p < 0.05 in univariable analysis comprised triple vessel disease,
stent length, and type C lesions in the group without CKD, and
age, type of DES, and type C lesions in the group with CKD. Even
after adjustment for other covariates, hsCRP levels remained
signiﬁcantly associated with MACE only in the group with CKD.
Discussion
This observational study found interaction between CKD and
the impact of preprocedural hsCRP on long-term clinical outcomes.
Preprocedural hsCRP levels were associated with poor outcomes
after PCI with ﬁrst-generation DES only in the patients with CKD.
These ﬁndings suggest that preprocedural hsCRP levels affect the
Table 2
Baseline clinical characteristics in patients without CKD.
Lowest tertile
T1 (n = 269)
<0.046 mg/dL
Middle tertile
T2 (n = 274)
0.047–0.155 mg/dL
Highest tertile
T3 (n = 272)
>0.156 mg/dL
p-Value
Age 65.1  9.2 64.8  8.7 64.4  9.9 0.71
Male, n (%) 224 (83.3) 238 (86.9) 225 (82.7) 0.35
Hypertension, n (%) 196 (72.9) 212 (77.4) 204 (75.0) 0.48
Dyslipidemia, n (%) 212 (78.8) 210 (76.6) 213 (78.3) 0.82
Diabetes, n (%) 132 (49.1) 136 (49.6) 135 (49.6) 0.99
Current smoking, n (%) 56 (20.8) 53 (19.3) 87 (32.0) < 0.01
Family history, n (%) 87 (32.3) 81 (29.6) 87 (32.0) 0.75
Multivessel disease, n (%) 175 (65.1) 171 (62.4) 201 (73.9) 0.012
Prior MI, n (%) 70 (26.0) 75 (27.4) 78 (28.7) 0.78
Prior CABG, n (%) 22 (8.2) 28 (10.2) 28 (10.3) 0.63
Prior PCI, n (%) 96 (35.7) 93 (33.9) 92 (33.8) 0.88
LVEF 62.5  10.2 62.2  11.1 61.5  10.7 0.53
BMI, kg/m2 23.9  2.9 24.7  3.0 24.9  3.8 <0.01
Waist circumference, cm 85.6  7.9 88.5  8.6 89.2  9.1 <0.01
SBP, mmHg 129.1  20.3 130.4  17.2 129.8  20.7 0.74
DBP, mmHg 69.9  11.7 70.5  11.3 70.0  13.2 0.80
LDL-C, mg/dL 105.0  29.5 108.7  29.5 111.1  30.7 0.06
HDL-C, mg/dL 46.7  11.6 44.3  10.9 41.7  10.9 <0.01
TG, mg/dL 129.4  65.7 144.4  65.9 148.4  80.2 <0.01
FBG, mg/dL 108.3  34.7 111.3  30.3 112.7  33.4 0.014
HbA1c, % 6.11  1.30 6.09  1.23 6.09  1.13 0.50
eGFR, mL/min/1.73 m2 76.8  12.6 77.2  14.3 76.4  13.3 0.82
CKD staging 0.94
Stage 1, n (%) 40 (14.9) 41 (15.0) 38 (14.0)
Stage 2, n (%) 229 (85.1) 233 (85.0) 234 (86.0)
Medication
Aspirin, n (%) 268 (100) 272 (99.3) 271 (100) 0.14
Thienopyridines, n (%) 265 (98.9) 268 (97.8) 267 (98.5) 0.24
Ca-blockers, n (%) 110 (41.0) 123 (44.9) 105 (38.8) 0.34
ACE inhibitors, n (%) 31 (11.6) 37 (13.5) 40 (14.8) 0.55
ARBs, n (%) 101 (37.7) 108 (39.4) 106 (39.1) 0.91
b-Blockers, n (%) 144 (53.7) 151 (55.1) 160 (59.0) 0.44
Statins, n (%) 202 (75.4) 189 (69.2) 192 (70.9) 0.26
Target lesion, n (%) 0.43
LMT 5 (1.9) 9 (3.3) 4 (1.5)
LAD 121 (45.0) 120 (43.8) 108 (39.7)
LCX 66 (24.5) 64 (23.4) 65 (23.9)
RCA 77 (28.6) 81 (29.6) 94 (34.6)
Type C, n (%) 144 (53.5) 149 (54.4) 152 (55.9) 0.86
LVEF, % 62.5  10.2 62.2  11.1 61.5  10.7 0.53
Reference lumen diameter, mm 2.70  0.41 2.73  0.42 2.76  0.45 0.20
Minimum lumen diameter, mm
At pre-procedure 0.44  0.35 0.45  0.35 0.43  0.28 0.98
At post-procedure 2.62  0.45 2.70  0.43 2.70  0.45 0.10
Type of stent 0.13
SES use, n (%) 199 (74.0) 214 (78.1) 192 (70.6)
PES use, n (%) 70 (26.0) 60 (21.9) 80 (29.4)
Number of stent, n 1.4  0.6 1.3  0.6 1.4  0.6 0.16
Mean stent size, mm 2.87  0.37 2.88  0.36 2.89  0.38 0.69
Total stent length, mm 28.5  16.5 28.7  15.4 30.0  16.3 0.42
ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CABG, coronary artery bypass graft surgery; CKD,
chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HDL-C, high-
density lipoprotein cholesterol; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery LDL-C, low-density lipoprotein cholesterol; LMT, left
main trunk; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stents; RCA, right coronary
artery; SBP, systolic blood pressure; SES, sirolimus-eluting stents; TG, triglyceride.
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with ﬁrst-generation DES implantation only when CKD co-exists.
Elevated preprocedural CRP levels are powerful predictors of
adverse clinical cardiovascular events after BMS [5,21]. The
predictive value of CRP for clinical outcomes after PCI in the
DES era has remained controversial [9,22]. Park et al. found
that preprocedural CRP did not predict restenosis after DES
implantation [9]. However, the absence of a relationship between
preprocedural hsCRP levels and clinical outcomes in their study
might be explained by the fact that half of the patients included in
their study had ACS. Indeed, another previous study of patients
without myocardial infarction identiﬁed preprocedural CRP as an
independent predictor of two-year clinical outcomes after PCIincluding death and myocardial infarction [23]. The present study
did not include patients with ACS to exclude the confounding effect
of myocardial necrosis on preprocedural CRP which can interfere
with the ability to detect potential of vascular inﬂammation.
In fact, we found a similar univariable relationship between
preprocedural hsCRP levels and MACE after PCI with ﬁrst-
generation DES. The present study also found an interaction
between CKD and hsCRP was associated with outcome. This might
partially explain the conﬂicting results of previous studies that
have assessed the prognostic impact of preprocedural hsCRP levels
after PCI with DES.
Renal dysfunction is closely associated with systemic athero-
sclerosis, which increases risk for cardiovascular events even in
Table 3
Baseline clinical characteristics in patients with CKD.
Lowest tertile
T1 (n = 120)
<0.058 mg/dL
Middle tertile
T2 (n = 119)
0.058–0.189 mg/dL
Highest tertile
T3 (n = 122)
>0.189 mg/dL
p-Value
Age 68.8  8.6 70.4  7.9 71.6  9.4 <0.05
Male, n (%) 100 (83.3) 103 (86.6) 98 (80.3) 0.43
Hypertension, n (%) 88 (73.3) 96 (80.7) 96 (78.7) 0.37
Dyslipidemia, n (%) 94 (78.3) 103 (86.6) 96 (78.7) 0.17
Diabetes, n (%) 58 (48.3) 62 (52.1) 60 (49.2) 0.83
Current smoking, n (%) 16 (13.3) 18 (15.1) 28 (23.0) 0.11
Family history, n (%) 37 (30.8) 35 (29.4) 38 (31.2) 0.95
Multivessel disease, n (%) 48 (78.7) 52 (83.9) 50 (84.7) 0.64
Prior MI, n (%) 36 (36.7) 29 (30.2) 31 (30.7) 0.56
Prior CABG, n (%) 9 (9.2) 18 (18.8) 14 (13.9) 0.15
Prior PCI, n (%) 53 (54.1) 52 (54.2) 45 (44.6) 0.30
LVEF 62.7  8.8 63.2  10.7 58.6  14.8 0.09
BMI, kg/m2 24.1  2.9 24.5  2.8 24.8  3.3 0.37
Waist circumference, cm 87.3  8.6 88.7  7.6 89.4  8.0 0.14
SBP, mmHg 131.9  21.9 132.0  21.6 133.3  19.2 0.70
DBP, mmHg 71.6  12.3 68.3  11.8 69.6  11.2 0.13
LDL-C, mg/dL 104.1  28.6 101.3  30.8 110.0  32.7 0.19
HDL-C, mg/dL 45.4  12.5 42.8  10.9 42.4  13.1 0.06
TG, mg/dL 133.1  67.4 146.3  69.9 139.4  71.0 0.18
FBG, mg/dL 104.2  32.9 110.5  41.6 106.7  37.2 0.29
HbA1c, % 5.89  0.98 5.91  0.99 6.17  1.20 0.24
eGFR, mL/min/1.73 m2 52.0  6.9 52.0  7.6 50.7  8.1 0.41
CKD staging 0.60
Stage 3, n (%) 119 (99.2) 117 (98.3) 119 (97.5)
Stage 4, n (%) 1 (0.8) 2 (1.7) 3 (2.5)
Medication
Aspirin, n (%) 118 (99.2) 116 (98.3) 122 (100) 0.68
Thienopyridines, n (%) 116 (97.5) 114 (96.6) 120 (98.3) 0.43
Ca-blockers, n (%) 55 (46.2) 59 (50.0) 54 (44.3) 0.66
ACE inhibitors, n (%) 18 (15.1) 12 (10.2) 16 (13.1) 0.51
ARBs, n (%) 54 (45.4) 53 (44.9) 54 (44.3) 0.98
b-Blockers, n (%) 64 (53.8) 72 (61.0) 64 (52.5) 0.36
Statins, n (%) 82 (68.9) 86 (72.9) 85 (69.7) 0.77
Target lesion, n (%) 0.55
LMT 3 (2.5) 5 (4.2) 3 (2.5)
LAD 57 (47.5) 49 (41.2) 51 (41.8)
LCX 28 (23.3) 28 (23.5) 32 (26.2)
RCA 32 (26.7 37 (31.1) 36 (29.5)
Type C, n (%) 60 (50.0) 70 (58.8) 75 (61.5) 0.17
Reference lumen diameter, mm 2.72  0.43 2.73  0.41 2.76  0.43 0.77
Minimum lumen diameter, mm
At pre-procedure 0.45  0.32 0.51  0.30 0.50  0.38 0.40
At post-procedure 2.63  0.40 2.67  0.43 2.68  0.37 0.53
Type of stent 0.28
SES use, n (%) 95 (79.2) 84 (70.6) 94 (77.1)
PES use, n (%) 25 (20.8) 35 (29.4) 28 (22.9)
Number of stent, n 1.4  0.7 1.3  0.7 1.3  0.5 0.71
Mean stent size, mm 2.86  0.35 2.88  0.36 2.90  0.33 0.75
Total stent length, mm 28.0  16.2 28.8  15.5 27.4  14.0 0.78
ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CABG, coronary artery bypass graft surgery; CKD,
chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HDL-C, high-
density lipoprotein cholesterol; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery LDL-C, low-density lipoprotein cholesterol; LMT, left
main trunk; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stents; RCA, right coronary
artery; SBP, systolic blood pressure; SES, sirolimus-eluting stents; TG, triglyceride.
M. Ogita et al. / Journal of Cardiology 66 (2015) 15–21 19patients with less severe forms such as CKD [24]. CKD is also
associated with endothelial dysfunction [25] and pronounced
neointimal hyperplasia after coronary stenting that leads to more
in-stent restenosis. Despite obvious reduction in the restenosis
rate due to DES implantation, renal dysfunction and/or CKD
are still associated with poor adverse clinical outcomes including
all-cause death, myocardial infarction, and angiographic restenosis
[26–28]. CKD has been described as a state of accelerated
atherosclerosis through several pathways including enhanced
vascular inﬂammation [15,16]. We found interactions between
presence or absence of CKD and preprocedural inﬂammatory
status in the vasculatures as well as clinical outcomes. Even after
adjustment for other covariates, the signiﬁcant association
between preprocedural hsCRP levels and long-term clinicaloutcomes in patients with stable CAD with CKD persisted. Choi
et al. similarly found that poor renal function and high hsCRP levels
were additively associated with mortality and myocardial infarc-
tion in an unselected population that was treated by PCI with DES
[29]. In addition, a previous study demonstrated the prognostic
impact of CRP levels on clinical outcome after implantation of
sirolimus-eluting stents in patients on hemodialysis [30]. Elevated
CRP levels are associated with major adverse outcomes including
cardiovascular death, non-fatal myocardial infarction, and target
lesion revascularization which is similar to the result of the present
study suggesting that increased preprocedural CRP values predict
the adverse outcomes after DES implantation in patients with CKD.
Several limitations of the present study require consideration.
This single-center, observational study included a small sample
Fig. 3. Kaplan–Meier curves for major adverse cardiovascular events (MACE) in
patients with chronic kidney disease.
Fig. 2. Kaplan–Meier curves for major adverse cardiovascular events (MACE) in
patients without chronic kidney disease.
Table 4
Cox proportional hazards model for MACE.
Univariate Multivariate
HR 95% CI p HR 95% CI p
hsCRP (lowest tertile as reference)
(a) Patients without CKD
Middle tertile 1.29 0.83–2.05 0.26 1.26 0.80–1.99 0.32
Highest tertile 1.51 0.97–2.37 0.07 1.43 0.92–2.25 0.11
(b) Patients with CKD
Middle tertile 2.06 1.07–4.16 0.03 1.86 0.97–3.76 0.06
Highest tertile 2.71 1.46–5.36 0.0014 2.39 1.27–4.75 0.0062
Adjusted for variables were age, gender, body mass index, waist, hypertension,
diabetes, current smoking, family history of coronary artery disease, prior
myocardial infarction, left ventricular ejection fraction, triple vessel disease,
type C lesion, stent size, stent length, type of drug-eluting stent, use of statin
and use of angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker. The latter covariates were added in this model if only they were
statistically signiﬁcant predictors of MACE (p < 0.05).
MACE, major adverse cardiovascular event; CKD, chronic kidney disease; HR,
hazard ratio; CI, conﬁdence interval; hsCRP, high sensitivity C-reactive protein.
M. Ogita et al. / Journal of Cardiology 66 (2015) 15–2120cohort, and other unknown confounding factors might have
affected outcomes regardless of adjustments in the statistical
analyses. In addition, the number of events in the present study
was relatively small which led to the absence of statistically
signiﬁcant differences in outcome measures. In fact, hsCRP levels
tended to be associated with clinical outcomes in the patients
without CKD, but the difference did not reach statistical signiﬁ-
cance because the cumulative event rate was lower than that of the
patients with CKD. Thus, an observational study of a larger cohort
is necessary. In the present study, follow-up angiography was
performed in 158 (86.6%) patients which is a relatively high
percentage. Routine angiographic follow-up after implantation of
DES may increase revascularization of non-ischemic lesions due to
the so-called oculostenotic reﬂex but has no impact on long-term
outcomes [31]. Since we deﬁned CKD as eGFR < 60 mL/min/
1.73 m2 in the absence of information about proteinuria and
structural kidney disease, some patients might have been
misclassiﬁed. Finally, we had no information about the patient
compliance with the prescribed medical therapy during follow-up.
In conclusion, elevated preprocedural serum hsCRP levels are
associated with long-term clinical outcomes in stable CAD patients
with CKD and might be useful to predict long-term adverse events
after ﬁrst-generation DES implantation in patients with CKD.
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